BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9689152)

  • 1. Hypotensive effects of an angiotensin II type 1 receptor antagonist differ between exercised and sedentary rats aged from 4 to 19 weeks.
    Fujii N; Nagashima S; Yukawa K; Miyauchi T; Maki S; Sakai S; Murakami K; Miyazaki H
    Jpn J Physiol; 1998 Jun; 48(3):215-8. PubMed ID: 9689152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional hemodynamic effects of candesartan cilexetil (TCV-116), an angiotensin II AT1-receptor antagonist, in conscious spontaneously hypertensive rats.
    Kanagawa R; Wada T; Sanada T; Ojima M; Inada Y
    Jpn J Pharmacol; 1997 Mar; 73(3):185-90. PubMed ID: 9127812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of an angiotensin II receptor antagonist, TCV-116, on cardiac hypertrophy and coronary circulation in spontaneously hypertensive rats.
    Takeda K; Fujita H; Nakamura K; Uchida A; Tanaka M; Itoh H; Nakata T; Sasaki S; Nakagawa M
    Blood Press Suppl; 1994; 5():94-8. PubMed ID: 7889211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypotensive activity of TCV-116, a newly developed angiotensin II receptor antagonist, in spontaneously hypertensive rats.
    Mizuno K; Niimura S; Tani M; Saito I; Sanada H; Takahashi M; Okazaki K; Yamaguchi M; Fukuchi S
    Life Sci; 1992; 51(20):PL183-7. PubMed ID: 1435062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of TCV-116 on endothelin-1 and PDGF A-chain expression in angiotensin II-induced hypertensive rats.
    Hara K; Kobayashi N; Nakano S; Mori Y; Tsubokou Y; Matsuoka H
    Hypertens Res; 2001 Jan; 24(1):55-64. PubMed ID: 11213031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent inhibition of the pressor and aldosterone responses to angiotensin-II by TCV-116 in normotensive subjects.
    Ogihara T; Nagano M; Higaki J; Kohara K; Mikami H
    J Cardiovasc Pharmacol; 1995 Sep; 26(3):490-4. PubMed ID: 8583793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal responses to angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor in partially nephrectomized spontaneously hypertensive rats.
    Okada H; Suzuki H; Kanno Y; Ikenaga H; Saruta T
    J Cardiovasc Pharmacol; 1995 Oct; 26(4):564-9. PubMed ID: 8569216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of AT1 receptor antagonist and spironolactone on cardiac expression of ET-1 mRNA in SHR-SP/Izm.
    Naruse M; Tanabe A; Hara Y; Takagi S; Imaki T; Takano K
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S1-3. PubMed ID: 15838251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the angiotensin II receptor antagonist, TCV-116, on blood pressure and the renin-angiotensin system in healthy subjects.
    Ogihara T; Nagano M; Mikami H; Higaki J; Kohara K; Azuma J; Aoki T; Hamanaka Y
    Clin Ther; 1994; 16(1):74-86. PubMed ID: 8205603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (+-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H- benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats.
    Inada Y; Wada T; Shibouta Y; Ojima M; Sanada T; Ohtsuki K; Itoh K; Kubo K; Kohara Y; Naka T
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1540-7. PubMed ID: 8138966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of hypertension and renal injury by salt-loading during chronic nitric oxide inhibition. Effects of TCV-116, a novel angiotensin II receptor antagonist.
    Okamura M; Konishi Y; Nishimura M; Umetani N; Iwai J; Negoro N; Inoue T; Takeda T; Kanayama Y
    Blood Press Suppl; 1994; 5():75-8. PubMed ID: 7889207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of chronic oral treatment with imidapril and TCV-116 on the responsiveness to angiotensin II in ventrolateral medulla of SHR.
    Tsuchihashi T; Kagiyama S; Matsumura K; Abe I; Fujishima M
    J Hypertens; 1999 Jul; 17(7):917-22. PubMed ID: 10419064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement in baroreflex function by an oral angiotensin receptor antagonist in rats with myocardial infarction.
    Nishizawa M; Kumagai H; Ichikawa M; Oshima N; Suzuki H; Saruta T
    Hypertension; 1997 Jan; 29(1 Pt 2):458-63. PubMed ID: 9039142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of an angiotensin II receptor antagonist, TCV-116, on insulin sensitivity in fructose-fed rats.
    Shimamoto K; Matsuda K; Takizawa H; Higashiura K; Ura N; Iimura O
    Blood Press Suppl; 1994; 5():113-6. PubMed ID: 7889192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the non-peptide angiotensin II receptor antagonist TCV-116 on systemic and renal hemodynamics in dogs with renal hypertension.
    Ito K; Shiomi M; Kito G
    Hypertens Res; 1995 Mar; 18(1):69-75. PubMed ID: 7584913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AT1 receptor antagonist prevents brain edema without lowering blood pressure.
    Ito H; Takemori K; Kawai J; Suzuki T
    Acta Neurochir Suppl; 2000; 76():141-5. PubMed ID: 11449994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effect of chronic inhibition of calcium channel and angiotensin II type 1-receptor on aldosterone synthesis in spontaneously hypertensive rats.
    Otsuka F; Ogura T; Kataoka H; Kishida M; Takahashi M; Mimura Y; Yamauchi T; Makino H
    J Steroid Biochem Mol Biol; 2000 Oct; 74(3):125-36. PubMed ID: 11086231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the hypotensive and hypoglycaemic actions of an angiotensin converting enzyme inhibitor, an AT1a antagonist and troglitazone.
    Chen S; Noguchi Y; Izumida T; Tatebe J; Katayama S
    J Hypertens; 1996 Nov; 14(11):1325-30. PubMed ID: 8934361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AT1 receptor antagonist, TCV 116, does not prevent cardiac hypertrophy in salt-loaded Dahl salt-sensitive rats.
    Sugimoto K; Gotoh E; Takasaki I; Ebina T; Iwamoto T; Takizawa T; Shionoiri H; Ishii M
    Clin Exp Pharmacol Physiol; 1996 Apr; 23(4):282-6. PubMed ID: 8717062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats.
    Naruse M; Tanabe A; Sato A; Takagi S; Tsuchiya K; Imaki T; Takano K
    Hypertension; 2002 Jul; 40(1):28-33. PubMed ID: 12105134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.